bluebird bio (BLUE) Set to Announce Earnings on Thursday

bluebird bio (NASDAQ:BLUE - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.47) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

bluebird bio Stock Performance

bluebird bio stock traded up $0.01 during midday trading on Tuesday, hitting $1.01. 3,504,920 shares of the company's stock were exchanged, compared to its average volume of 8,775,221. bluebird bio has a 12-month low of $0.85 and a 12-month high of $5.53. The stock has a market cap of $110.43 million, a price-to-earnings ratio of -1.36 and a beta of 0.82. The firm's 50 day simple moving average is $1.23 and its 200 day simple moving average is $1.88.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wedbush lowered their target price on shares of bluebird bio from $1.72 to $1.68 and set a "neutral" rating on the stock in a report on Tuesday, March 19th. Wells Fargo & Company lowered their target price on shares of bluebird bio from $4.00 to $3.00 and set an "equal weight" rating on the stock in a report on Wednesday, March 27th. StockNews.com raised shares of bluebird bio to a "sell" rating in a report on Thursday, March 28th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $6.00 target price on shares of bluebird bio in a report on Wednesday, March 27th. Finally, HSBC lowered their target price on shares of bluebird bio from $2.31 to $1.02 and set a "reduce" rating on the stock in a report on Tuesday, March 5th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $5.74.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.